Rozlytrek (entrectinib) — United Healthcare
Metastatic non-small cell lung cancer (NSCLC)
Initial criteria
- Diagnosis of metastatic non-small cell lung cancer (NSCLC)
- Disease is ROS1-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Rozlytrek therapy
Approval duration
12 months